This website uses its own and third party technical cookies, solely to ensure enhanced navigation and to gather anonymous statistical navigation data without any user profiling.

If you wish to learn more or deny consent to all or some cookies click here.

If you access any element below this banner you automatically consent to the use of cookies.

Accept

  1. Galileo Research »
  2. Opportunità per Investitori »
  3. Partners

Partners

Galileo Research is seeking a partner to raise funding for Phase II and Phase III development for TALL-104 program in ovarian cancer.

 

Ovarian cancer is the second most common gynecological malignancy among women. Among the seven major markets, it has affected around 170,000 women in 2010, with the UK having the highest prevalence among the top five EU countries.

 

The prevalence of ovarian cancer is set to grow from 170,280 in 2010 to 174,429 in 2016. Approximately 70% of the patients with ovarian cancer are diagnosed with advanced disease. The standard treatment includes surgery, followed by a combination of platinum and taxane adjuvant chemotherapy.